Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 8 records in total 8
    records per page




    Incidence, risk factors and mortality outcome in patients with acute kidney injury MESHD acute kidney injury HP in COVID-19: a single-center observational study

    Authors: Gaetano Alfano; Annachiara Ferrari; Francesco Fontana; Giacomo Mori; Riccardo Magistroni; Meschiari Marianna; Franceschini Erica; Marianna Menozzi; Gianluca Cuomo; Gabriella Orlando; Antonella Santoro; Margherita Di Gaetano; Cinzia Puzzolante; Federica Carli; Andrea Bedini; Jovana Milic; Paolo Raggi; Massimo Girardis; Cristina Mussini; Gianni Cappelli; Giovanni Guaraldi

    doi:10.1101/2020.06.24.20138230 Date: 2020-06-24 Source: medRxiv

    Background Acute kidney injury MESHD Acute kidney injury HP (AKI) is a recently recognized complication of coronavirus disease MESHD-2019 (COVID-19). This study aims to evaluate the incidence, risk factors and case-fatality rate of AKI in patients with documented COVID-19. Methods We reviewed the health medical records of 307 consecutive patients hospitalized for symptoms of COVID-19 at the University Hospital of Modena, Italy. Results AKI was diagnosed in 69 out of 307 (22.4%) patients. The stages of AKI were stage 1 in 57.9%, stage 2 in 24.6% and stage 3 in 17.3%. Hemodialysis was performed in 7.2% of the subjects. AKI patients had a mean age TRANS of 74.7 {+/-} 9.9 years and higher serum SERO levels of the main marker of inflammation MESHD and organ involvement (lung, liver, hearth and liver) than non-AKI patients. AKI events were more frequent in subjects with severe lung comprise. Two peaks of AKI events coincided with in-hospital admission and death MESHD of the patients. Kidney injury was associate with a higher rate of urinary abnormalities including proteinuria MESHD proteinuria HP (0.448{+/-} 0.85 vs 0.18 {+/-} 0.29; P=<0.0001) and hematuria MESHD hematuria HP (P=0.032) compared to non-AKI patients. At the end of follow-up, 65.2% of the patients did not recover their renal function after AKI. Risk factors for kidney injury were age TRANS, male TRANS sex, CKD and non-renal SOFA. Adjusted Cox regression analysis revealed that AKI was independently associated with in-hospital death MESHD (hazard ratio [HR]=3.74; CI 95%, 1.34-10.46) compared to non-AKI patients. Groups of patients with AKI stage 2-3 and failure to recover kidney function were associated with the highest risk of in-hospital mortality. Lastly, long-hospitalization was positively associated with a decrease of serum creatinine HP serum SERO creatinine, likely due to muscle depletion occurred with prolonged bed rest. Conclusions AKI was a dire consequence of patients with COVID-19. Identification of patients at high-risk for AKI and prevention of kidney injury by avoiding dehydration MESHD dehydration HP and nephrotoxic agents is imperative in this vulnerable cohort of patients.

    Clinical and pathological findings of SARS-CoV-2 infection MESHD and concurrent IgA nephropathy HP: A case report

    Authors: Liu Liu

    doi:10.21203/rs.3.rs-35388/v1 Date: 2020-06-14 Source: ResearchSquare

    Background: Since the Coronavirus Disease MESHD 2019 (COVID-19) outbreak, there is limited data on the clinical characteristics, treatment strategies and prognosis of COVID-19 in patients with concurrent renal disease MESHD. The kidney is believed to have a predisposition for COVID-19 due to its abundant angiotensin-converting enzyme 2 (ACE2) expression, which acts as a cell entry receptor for the severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2). Recent postmortem investigations reveal renal involvement in COVID-19, and case reports describe collapsing glomerulopathy HP in African American patients with COVID-19. However, there is limited data regarding IgA nephropathy HP in the setting of COVID-19.Case presentation: In the present case, we report a 65-year old Chinese woman who presented with macroscopic hematuria HP hematuria MESHD, worsening proteinuria MESHD proteinuria HP and decreased renal function after COVID-19 infection MESHD. She received a renal biopsy during COVID-19 infection MESHD. The renal biopsy revealed IgA nephropathy HP without any evidence for SARS-Cov-2. The findings suggest that the renal abnormalities were a consequence of exacerbation of this patient’s underlying glomerular disease MESHD after COVID-19 infection MESHD. After a regimen of 3-day course of glucocorticoid and angiotensin II receptor blocker therapy, the patient recovered and remained stable upon follow-up. Conclusions: It is important to consider the underlying glomerular disease MESHD exacerbation rather than virus induced injury when dealing with renal abnormalities in patients with COVID-19.

    Incidence and risk factors of kidney impairment on patients with COVID-19: a systematic review and meta-analysis

    Authors: Qixin Yang; Xiyao Yang

    doi:10.1101/2020.05.28.20116400 Date: 2020-06-03 Source: medRxiv

    Background: The novel coronavirus is pandemic around the world. Several researchers have given the evidence of impacts of COVID-19 on the respiratory, cardiovascular and gastrointestinal system. Studies still have debated on kidney injury of COVID-19 patients. The purpose of the meta-analysis was to evaluate the association of kidney impairment with the development of COVID-19. Methods: The PubMed, Embase and MedRxiv databases were searched until April 1, 2020. We extracted data from eligible studies to summarize the clinical manifestations and laboratory indexes of kidney injury on COVID-19 infection MESHD patients and further compared the prevalence SERO of acute kidney injury MESHD acute kidney injury HP (AKI) and the mean differences of three biomarkers between in ICU/severe and non-ICU/non-severe cases. Heterogeneity was evaluated using the I2 method. Results: In the sum of 19 studies with 4375 patients were included in this analysis. The pooled prevalence SERO of AKI, increased serum SERO creatinine (Scr), increased blood urea nitrogen HP blood SERO urea nitrogen (BUN), increased D-dimer, proteinuria MESHD proteinuria HP and hematuria MESHD hematuria HP in patients with COVID-19 were 7.7%, 6.6%, 6.2%, 49.8%, 42% and 30.3% respectively. Moreover, the means of Scr, BUN and D-dimer were shown 6-folds, 1.8-folds and 0.68-folds, respectively, higher in ICU/severe cases than in corresponding non-ICU/non-severe patients. The prevalence SERO of AKI was about 17 folds higher in ICU/severe patients compared with the non-ICU/non-severe cases. Conclusions: Overall, we assessed the incidences of the clinic and laboratory features of kidney injury in COVID-19 patients. And kidney dysfunction may be a risk factor for COVID-19 patients developing into the severe condition. In reverse, COVID-19 can also cause damage to the kidney.

    Characterisation of Acute Kidney Injury MESHD Acute Kidney Injury HP in Critically Ill Patients with Severe Coronavirus Disease MESHD-2019 (COVID-19)

    Authors: Sebastien RUBIN; Arthur Orieux; Renaud Prevel; Antoine Garric; Marie-Lise Bats; Sandrine Dabernat; Fabrice Camou; Olivier Guisset; Nahema Issa; Gaelle Mourissoux; Antoine Dewitte; Olivier Joannes-boyau; Catherine Fleureau; Hadrien Roze; Cedric Carrie; Laurent Petit; Benjamin Clouzeau; Charline Sazio; Hoang-Nam Bui; Odile Pillet; Claire Rigothier; Frederic Vargas; Christian Combe; Didier Gruson; Alexandre Boyer

    doi:10.1101/2020.05.06.20069872 Date: 2020-05-10 Source: medRxiv

    Background: COVID19-associated acute kidney injury MESHD acute kidney injury HP frequency, severity and characterisation in critically ill patients has not been reported. Methods: Single-center cohort performed from March 3, 2020, to April 14, 2020 in 4 intensive care units in Bordeaux University Hospital, France. All patients with COVID19 and pulmonary severity criteria were included. AKI was defined using KDIGO criteria. A systematic urinary analysis was performed. The incidence, severity, clinical presentation, biological characterisation (transient vs. persistent acute kidney injury MESHD acute kidney injury HP; proteinuria MESHD proteinuria HP, hematuria MESHD hematuria HP and glycosuria MESHD glycosuria HP), and short-term outcomes was evaluated. Results: 71 patients were included, with basal serum SERO creatinine of 69 +/- 21 micromol/L. At admission, AKI was present in 8/71 (11%) patients. Median follow-up was 17 [12-23] days. AKI developed in a total of 57/71 (80%) patients with 35% Stage 1, 35% Stage 2, and 30% Stage 3 acute kidney injury MESHD acute kidney injury HP; 10/57 (18%) required renal replacement therapy. Transient AKI was present in only 4/55 (7%) patients and persistent AKI was observed in 51/55 (93%). Patients with persistent AKI developed a median urine protein/creatinine of 82 [54-140] (mg/mmol) with an albuminuria MESHD albuminuria HP/ proteinuria MESHD proteinuria HP ratio of 0.23 +/- 20 indicating predominant tubulo-interstitial injury. Only 2 (4%) patients had glycosuria MESHD glycosuria HP. At Day 7 onset of after AKI, six (11%) patients remained dependent on renal replacement therapy, nine (16%) had SCr > 200 micromol/L, and four (7%) died. Day 7 and day 14 renal recovery occurred in 28% and 52 % respectively. Conclusion: COVID19 associated AKI is frequent, persistent severe and characterised by an almost exclusive tubulo-interstitial injury without glycosuria MESHD glycosuria HP

    Kidney Diseases MESHD and COVID-19 Pandemic: A Review Article

    Authors: Tarek Abdelaziz

    id:10.20944/preprints202004.0289.v1 Date: 2020-04-16 Source: Preprints.org

    In December 2019, an animal human coronavirus transmission TRANS occurred in Wuhan, China. A state of global pandemic was shortly declared, among a very rapid contagious spread of the virus. The causative virus was identified as SARS CoV 2 virus and is genetically related to the previous SARS outbreak in 2003. The virus causes wide clinical spectrum from mild flu like symptoms to adult respiratory distress syndrome MESHD adult TRANS respiratory distress HP syndrome. Kidney involvement has been reported in several reports in patients with various degrees of severity of SARS CoV2 infection MESHD. As knowledge is evolving, the accurate incidence of AKI is not known. Many questions are yet to be answered as regards the effect of epidemiological variables and comorbidities on the occurrence of AKI. Some reports have observed the occurrence of hematuria MESHD hematuria HP and proteinuria MESHD proteinuria HP in a percentage of infected patients. Moreover, chronic kidney disease HP kidney disease MESHD has not been found in some reports to add to the adverse outcomes, an aspect that merits further exploration. Patients on regular hemodialysis may be vulnerable to contagion due to lower status of immunity and need for frequent attendance to healthcare facilities. Due to the previous factors, prevention and mitigation of SARS CoV2 virus in this vulnerable population constitutes a major challenge.

    Urinalysis, but not blood SERO biochemistry, detects the early renal-impairment in patients with COVID-19

    Authors: Haifeng zhou Jr.; Zili Zhang Jr.; Heng Fan Sr.; Junyi Li Jr.; Mingyue Li Jr.; Yalan Dong Jr.; Weina Guo Jr.; Lan Lin Jr.; Zhenyu Kang Jr.; Ting Yu Jr.; Chunxia Tian Jr.; Yang Gui Jr.; Renjie Qin Jr.; Haijun Wang Sr.; ShanShan Luo Sr.; Desheng Hu

    doi:10.1101/2020.04.03.20051722 Date: 2020-04-06 Source: medRxiv

    Background: In December 2019, a novel coronavirus (SARS-CoV-2) caused infectious disease MESHD, termed COVID-19, outbroke in Wuhan, China. COVID-19 patients manifested as lung injury MESHD with complications in other organs, such as liver, heart, gastrointestinal tract, especially for severe cases. However, whether COVID-19 causes significant acute kidney injury MESHD acute kidney injury HP (AKI) remained controversial. Methods: We retrospectively analyzed the clinical characteristics, urine and blood SERO routine tests and other laboratory parameters of hospitalized COVID-19 patients in Wuhan Union Hospital. Findings: 178 patients, admitted to Wuhan Union hospital from February 02 to February 29, 2020, were included in this study. No patient (0 [0%]) presented increased serum SERO creatinine (Scr), and 5 (2.8%) patients showed increased blood urea nitrogen HP blood SERO urea nitrogen (BUN), indicating few cases with kidney dysfunction. However, for patients (83) with no history of kidney disease MESHD who received routine urine test upon hospitalization, 45 (54.2%) patients displayed abnormality in urinalysis, such as proteinuria MESHD proteinuria HP, hematuria MESHD hematuria HP and leukocyturia, while none of the patients was recorded to have acute kidney injury MESHD acute kidney injury HP (AKI) throughout the study. Meanwhile, the patients with abnormal urinalysis usually had worse disease progression MESHD reflecting by laboratory parameters presentations, including markers of liver injury, inflammation MESHD, and coagulation. Conclusion: Many patients manifested by abnormal urinalysis on admission, including proteinuria MESHD proteinuria HP or hematuria MESHD hematuria HP. Our results revealed that urinalysis is better in unveiling potential kidney impairment of COVID-19 patients than blood SERO chemistry test and urinalysis could be used to reflect and predict the disease MESHD severity. We therefore recommend pay more attention in urinalysis and kidney impairment in COVID-19 patients.

    Kidney impairment is associated with in-hospital death MESHD of COVID-19 patients

    Authors: Yichun Cheng; Ran Luo; Kun Wang; Meng Zhang; Zhixiang Wang; Lei Dong; Junhua Li; Ying Yao; Shuwang Ge; Gang Xu

    doi:10.1101/2020.02.18.20023242 Date: 2020-02-20 Source: medRxiv

    Background: Information on kidney impairment in patients with coronavirus disease MESHD 2019 (COVID-19) is limited. This study aims to assess the prevalence SERO and impact of abnormal urine analysis and kidney dysfunction in hospitalized COVID-19 patients in Wuhan. Method: We conducted a consecutive cohort study of COVID-19 patients admitted in a tertiary teaching hospital with 3 branches following a major outbreak in Wuhan in 2020. Hematuria MESHD Hematuria HP, proteinuria MESHD proteinuria HP, serum SERO creatinine concentration and other clinical parameters were extracted from the electronic hospitalization databases and laboratory databases. Incidence rate for acute kidney injury MESHD acute kidney injury HP (AKI) was examined during the study period. Association between kidney impairment and in-hospital death MESHD was analyzed. Results: We included 710 consecutive COVID19 patients, 89 (12.3%) of whom died in hospital. The median age TRANS of the patients was 63 years (inter quartile range, 51-71), including 374 men and 336 women. On admission, 44% of patients have proteinuria MESHD proteinuria HP hematuria MESHD hematuria HP and 26.9% have hematuria MESHD hematuria HP, and the prevalence SERO of elevated serum creatinine HP serum SERO creatinine and blood SERO urea nitrogen were 15.5% and 14.1% respectively. During the study period, AKI occurred in 3.2% patients. Kaplan-Meier analysis demonstrated that patients with kidney impairment have higher risk for in-hospital death MESHD. Cox proportional hazard regression confirmed that elevated serum creatinine HP serum SERO creatinine, elevated urea nitrogen, AKI, proteinuria MESHD proteinuria HP and hematuria MESHD hematuria HP was an independent risk factor for in-hospital death MESHD after adjusting for age TRANS, sex, disease MESHD severity, leukocyte count and lymphocyte count. Conclusion: The prevalence SERO of kidney impairment ( hematuria MESHD hematuria HP, proteinuria MESHD proteinuria HP and kidney dysfunction) in hospitalized COVID-19 patients was high. After adjustment for confounders, kidney impairment indicators were associated with higher risk of in-hospital death MESHD. Clinicians should increase their awareness of kidney impairment in hospitalized COVID-19 patients.

    Caution on Kidney Dysfunctions of 2019-nCoV Patients

    Authors: - Anti-2019-nCoV Volunteers; Zhen Li; Ming Wu; Jiwei Yao; Jie Guo; Xiang Liao; Siji Song; Jiali Li; Guangjie Duan; Yuanxiu Zhou; Xiaojun Wu; Zhansong Zhou; Taojiao Wang; Ming Hu; Xianxiang Chen; Yu Fu; Chong Lei; Hailong Dong; Chuou Xu; Yahua Hu; Min Han; Yi Zhou; Hongbo Jia; Xiaowei Chen; Junan Yan

    doi:10.1101/2020.02.08.20021212 Date: 2020-02-12 Source: medRxiv

    Summary Background: To date, large amounts of epidemiological and case study data have been available for the Coronavirus Disease MESHD 2019 (COVID-19), which suggested that the mortality was related to not just respiratory complications. Here, we specifically analyzed kidney functions in COVID-19 patients and their relations to mortality. Methods: In this multi-centered, retrospective, observational study, we included 193 adult TRANS patients with laboratory-confirmed COVID-19 from 2 hospitals in Wuhan, 1 hospital in Huangshi (Hubei province, 83 km from Wuhan) and 1 hospital in Chongqing (754 km from Wuhan). Demographic data, symptoms, laboratory values, comorbidities, treatments, and clinical outcomes were all collected, including data regarding to kidney functions. Data were compared among three groups: non-severe COVID-19 patients (128), severe COVID-19 patients (65) and a control group of other pneumonia MESHD pneumonia HP (28). For the data from computed tomographic (CT) scans, we also included a control group of healthy subjects (110 cases, without abnormalities in the lung and without kidney diseases MESHD). The primary outcome was a common presence of kidney dysfunctions in COVID-19 patients and the occurrence of acute kidney injury MESHD acute kidney injury HP (AKI) in a fraction of COVID-19 patients. Secondary outcomes included a survival analysis of COVID-19 patients in conditions of AKI or comorbid chronic illnesses. Findings: We included 193 COVID-19 patients (128 non-severe, 65 severe (including 32 non-survivors), between January 6th and February 21th,2020; the final date of follow-up was March 4th, 2020) and 28 patients of other pneumonia MESHD pneumonia HP (15 of viral pneumonia MESHD pneumonia HP, 13 of mycoplasma pneumonia MESHD pneumonia HP) before the COVID-19 outbreak. On hospital admission, a remarkable fraction of patients had signs of kidney dysfunctions, including 59% with proteinuria MESHD proteinuria HP, 44% with hematuria MESHD hematuria HP, 14% with increased levels of blood SERO urea nitrogen, and 10% with increased levels of serum SERO creatinine, although mild but worse than that in cases with other pneumonia MESHD pneumonia HP. While these kidney dysfunctions might not be readily diagnosed as AKI at admission, over the progress during hospitalization they could be gradually worsened and diagnosed as AKI. A univariate Cox regression analysis showed that proteinuria MESHD proteinuria HP, hematuria MESHD hematuria HP, and elevated levels of blood SERO urea nitrogen, serum SERO creatinine, uric acid as well as D-dimer were significantly associated with the death MESHD of COVID-19 patients respectively. Importantly, the Cox regression analysis also suggested that COVID-19 patients that developed AKI had a ~5.3-times mortality risk of those without AKI, much higher than that of comorbid chronic illnesses (~1.5 times risk of those without comorbid chronic illnesses). Interpretation: To prevent fatality in such conditions, we suggested a high degree of caution in monitoring the kidney functions of severe COVID-19 patients regardless of the past disease MESHD history. In addition, upon day-by-day monitoring, clinicians should consider any potential interventions to protect kidney functions at the early stage of the disease MESHD and renal replacement therapies in severely ill patients, particularly for those with strong inflammatory reactions or a cytokine storm. Funding: None.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.